What this overview covers
This article summarizes notable vaping research from 2019, with an emphasis on study design, key findings, and limitations. It explains how specific studies relate to public health questions, from short-term physiological effects to population-level trends. The aim is to provide a durable, evidence-based reference that remains useful as the scientific landscape evolves.
Study landscape in 2019
By 2019, research on e-cigarettes and vaping had expanded beyond acute toxicity to include longitudinal patterns, product variability, and population behavior. Studies increasingly focused on real-world use, biomarker validation, and comparisons with combustible cigarettes. This period also saw more large-cohort investigations and systematic reviews, though many studies remained limited by short follow-up windows and narrow product ranges.
Types of studies and common limitations
Much of the 2019 evidence came from observational surveys, case series, and cross-sectional analyses. Randomized trials were rare and typically small. Common constraints included self-reported exposure, lack of long-term outcomes, and rapidly changing product formulations. Many investigations focused on youth, pregnant populations, or adult smokers switching completely or partially to vaping.
Notable studies and findings
Key peer-reviewed work in 2019 addressed biomarkers of exposure, toxicant exposure differences, and behavioral patterns among users. Several studies examined whether vaping served as a bridge to smoking or as a cessation aid, while others quantified contaminant levels and device performance variability.
Acute physiological effects
Short-term research in 2019 indicated measurable changes in heart rate, arterial stiffness, and airway resistance after vaping, often within minutes of use. Some studies reported reversible declines in lung function, while others found minimal acute impact in never-users who did not inhale. These effects were generally smaller than those observed with combustible cigarettes but were not always absent.
Exposure to toxicants and product variation
Laboratory and user studies consistently showed that e-cigarette aerosol contained lower levels of many toxicants compared with cigarette smoke, yet substances such as nicotine, formaldehyde-forming agents, and flavor chemicals were still present. Levels varied widely by device type, e-liquid composition, voltage settings, and user puffing behavior, complicating direct comparisons.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Primary focus | Biomarker validation and toxicant profiles | Peer-reviewed studies |
| Typical cohort size in 2019 studies | Small to moderate (tens to low hundreds) | Observational |
| Major limitations noted | Short follow-up, self-report, product variability | Methodological reviews |
| Public health context | Harm reduction relative to smoking, but uncertain long-term risk | Systematic reviews |
| Key populations studied | Youth, adults switching from smoking, pregnant individuals | Epidemiological surveys |
Behavioral patterns and population trends
Surveys in 2019 highlighted rising prevalence of vaping among adolescents and young adults, driven largely by flavored products and nicotine-salts delivery systems. Use among adult smokers showed more variability, with some studies indicating that vaping was more common among current smokers and recent quitters than among never-smokers.
Youth and young adult use
National and subnational monitoring consistently reported increases in past-30-day vaping among secondary and post-secondary students between 2017 and 2019. Correlates included peer use, flavored product availability, and lower perceived harm compared with smoking, though many youth reported intentions to quit. The stability of these patterns over subsequent years remained uncertain.
Adult smokers and cessation attempts
Among adult smokers, vaping was frequently employed as a harm-reduction tool or as a cessation aid, though dual use remained common. Population-level studies suggested that vaping was associated with higher quit attempts, but causal attribution to sustained abstinence was difficult to establish due to confounding factors and heterogeneity in vaping products and behaviors.
Regulatory and research context
In 2019, many jurisdictions were adapting policies to address youth vaping, product marketing, and ingredient restrictions. Concurrently, researchers emphasized the need for standardized exposure metrics, long-term cohorts, and head-to-head comparisons with other nicotine-delivery products. These calls shaped study designs in the following years and highlighted gaps in understanding chronic disease outcomes.
Key research gaps identified
- Long-term respiratory and cardiovascular outcomes
- Standardized measurement of exposure across devices and liquids
- Representative samples of diverse user profiles and product types
- Objective biobehavioral data linking patterns of use to health impacts
- Comparative effectiveness of vaping versus approved cessation aids
Interpretation and public health relevance
Taken together, the 2019 studies suggested that vaping is generally associated with lower exposure to toxicants than smoking, but that this difference does not equate to proven long-term safety. Acute effects were usually milder than those from cigarettes, yet not absent, particularly among sensitive groups. The role of vaping in population-level harm reduction remained plausible but unconfirmed, owing to limited high-quality longitudinal evidence.
Conclusion
Vaping research in 2019 advanced measurement of biomarkers and toxicants, clarified patterns of youth and adult use, and underscored important methodological limitations. While evidence pointed to reduced exposure relative to smoking for many users, questions about long-term health effects, real-world effectiveness as cessation tools, and impacts on youth remained central to ongoing inquiry. This synthesis is designed to remain relevant as new studies refine understanding of vaping-related risks and benefits.